These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37011599)

  • 41. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
    Saito S; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Nakamura M
    Circ J; 2014; 78(7):1684-92. PubMed ID: 24759796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention.
    Ahn KT; Seong SW; Choi UL; Jin SA; Kim JH; Lee JH; Choi SW; Jeong MH; Chae SC; Kim YJ; Kim CJ; Kim HS; Cho MC; Gwon HC; Jeong JO; Seong IW;
    Medicine (Baltimore); 2019 Mar; 98(11):e14833. PubMed ID: 30882670
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
    Melloni C; Cornel JH; Hafley G; Neely ML; Clemmensen P; Zamoryakhin D; Prabhakaran D; White HD; Fox KA; Ohman EM; Armstrong PW; Roe MT
    Eur Heart J Acute Cardiovasc Care; 2016 Oct; 5(6):443-454. PubMed ID: 26228448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
    Yoon HY; Lee N; Seong JM; Gwak HS
    Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical review of prasugrel for formulary decision makers.
    Schafer JA; Kjesbo NK; Gleason PP
    J Manag Care Pharm; 2009 May; 15(4):335-43. PubMed ID: 19422273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
    Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
    Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
    EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
    Motovska Z; Hlinomaz O; Kala P; Hromadka M; Knot J; Varvarovsky I; Dusek J; Jarkovsky J; Miklik R; Rokyta R; Tousek F; Kramarikova P; Svoboda M; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    J Am Coll Cardiol; 2018 Jan; 71(4):371-381. PubMed ID: 29154813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Weintraub W; Rao SV; Vogel B; Claessen B; Kini A; Effron M; Ge Z; Keller S; Strauss C; Snyder C; Toma C; Weiss S; Aquino M; Baker B; Defranco A; Bansilal S; Muhlestein B; Kapadia S; Pocock S; Poddar KL; Henry TD; Mehran R
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):53-60. PubMed ID: 30656812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
    Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
    JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
    Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.
    Kitahara H; Tateishi K; Shiko Y; Inaba Y; Kobayashi Y; Inoue T
    PLoS One; 2022; 17(7):e0272140. PubMed ID: 35901007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Gill K; Servati N; Flahive J; Fraielli K
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
    Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
    Orban M; Kleeberger J; Ouarrak T; Freund A; Feistritzer HJ; Fuernau G; Geisler T; Huber K; Dudek D; Noc M; Montalescot G; Neumer A; Haller P; Clemmensen P; Zeymer U; Desch S; Massberg S; Schneider S; Thiele H; Hausleiter J
    Clin Res Cardiol; 2021 Sep; 110(9):1493-1503. PubMed ID: 33999281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.